Journal of Clinical Oncology · 2008 · 50 citations · 0 references
MedicineOncologyPharmacotherapyCancer PharmacologyChemotherapyOncology PharmacotherapyMetastatic Cancer ManagementMetastatic Disease ManagementMetastatic Disease TreatmentPancreatic CancerComplete Response AssessmentGemcitabine-based TherapyMetastatic Pancreatic CancerPancreatic Cancer PharmacotherapyPhase Iii Oncology TrialsSample Size Calculation
4507 Background: The phase II B+G trial showed a 21% response rate (RR) with a median overall survival (OS) of 8.8 months [Kindler, JCO 2005]. In the phase III OS trial of G+E vs. G the hazard ratio (HR) was 0.82 (95% CI 0.69–0.99; p=0.0328) [Moore, JCO 2007]. Therefore, a phase III trial exploring GE±B was conducted. Methods: Eligible pts had chemonaive, metastatic pancreatic adenocarcinoma and KPS 60–100. The primary endpoint was OS. The sample size allowed the detection of a 30% improvement in median OS (6.9 vs. 9.0 mo, 80% power). Pts received B/P at 5 mg/kg q2w (IV) added to daily E (100 mg/day PO) and G (1,000 mg/m2 30 min IV) given weekly for 7 weeks during first 8-weekly cycle, followed by weekly for 3 weeks during subsequent 4-weekly cycles. CT scans were performed every 8 weeks. Results: 607 pts were enrolled (Jul05-Sep06). Pt characteristics (301GE-P/306GE-B): male 62%/57%; median age 61y/62y; KPS <80 13%/13%. Median duration of follow-up: 177/203 days. As of Mar07 454 pts (233/221) had died. Median OS 6.0/7.1 mo (HR 0.89; 95% CI 0.74–1.07). Median PFS 3.6/4.6 mo (HR 0.73; 95% CI 0.61–0.86; p=0.0002). Response: complete response 0%/0.7%; partial response 8.6%/12.8%, progressive disease 24.3%/19.9%. Grade 3–4 AEs: no clinically relevant difference observed (see table). Hypertension (Gr 3): 1%/3%; GI perforation 1%/<1%. All grade AEs: bleeding: 23%/42% (mainly epistaxis, 11%/29%); proteinuria 1%/5%; venous thrombosis 18%/15%. Multiple cox regression analysis was performed on OS adjusting for baseline covariates. Conclusion: Addition of B to GE did not lead to significantly longer OS, but there was a trend towards improved OS (95% CI 0.74–1.07) with significantly improved PFS (p=0.0002) in metastatic pancreatic cancer. GEB was very well tolerated. A further update of the data is planned in early 2008. Grade 3 - 4 AEs GE-P (N-287) GE-B (N-296) Pts % Pts % Neutropenia 50 17 62 21 Anemia 26 9 20 7 Thrombocytopenia 18 6 24 8 Fatigue 19 7 16 5 Rash 9 3 23 8 Diarrhea 16* 6 11 4 *1 pt died Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Hoffmann-La Roche Hoffmann-La Roche Hoffmann-La Roche Hoffmann-La Roche Hoffmann-La Roche Hoffmann-La Roche